Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALZN NASDAQ:CTXR NASDAQ:GNTA NASDAQ:HOOK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALZNAlzamend Neuro$1.15+1.8%$1.19$0.84▼$8.22$4.30M0.1160,765 shs62,953 shsCTXRCitius Pharmaceuticals$0.70-0.6%$0.75$0.48▼$2.48$19.25M1.05905,095 shs541,001 shsGNTAGenenta Science$0.60+3.0%$0.68$0.55▼$10.00$13.68M0.7446,628 shs29,834 shsHOOKHOOKIPA Pharma$1.18+4.9%$1.13$0.81▼$1.65$14.55M0.8411,299 shs65,007 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALZNAlzamend Neuro0.00%+10.78%+1.80%-45.93%-69.04%CTXRCitius Pharmaceuticals0.00%+33.04%-8.95%-6.48%-0.27%GNTAGenenta Science0.00%-8.18%-18.10%-38.89%-86.48%HOOKHOOKIPA Pharma0.00%-5.43%+2.31%+11.43%-25.47%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALZNAlzamend Neuro$1.15+1.8%$1.19$0.84▼$8.22$4.30M0.1160,765 shs62,953 shsCTXRCitius Pharmaceuticals$0.70-0.6%$0.75$0.48▼$2.48$19.25M1.05905,095 shs541,001 shsGNTAGenenta Science$0.60+3.0%$0.68$0.55▼$10.00$13.68M0.7446,628 shs29,834 shsHOOKHOOKIPA Pharma$1.18+4.9%$1.13$0.81▼$1.65$14.55M0.8411,299 shs65,007 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALZNAlzamend Neuro0.00%+10.78%+1.80%-45.93%-69.04%CTXRCitius Pharmaceuticals0.00%+33.04%-8.95%-6.48%-0.27%GNTAGenenta Science0.00%-8.18%-18.10%-38.89%-86.48%HOOKHOOKIPA Pharma0.00%-5.43%+2.31%+11.43%-25.47%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALZNAlzamend Neuro 2.00Hold$28.002,334.78% UpsideCTXRCitius Pharmaceuticals 2.25Hold$5.00617.36% UpsideGNTAGenenta Science 1.00SellN/AN/AHOOKHOOKIPA Pharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ALZN, GNTA, HOOK, and CTXR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2026ALZNAlzamend Neuro Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)5/19/2026CTXRCitius Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/18/2026CTXRCitius Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.005/6/2026ALZNAlzamend Neuro Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)3/27/2026CTXRCitius Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026GNTAGenenta Science Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/11/2026CTXRCitius Pharmaceuticals D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.00(Data available from 5/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALZNAlzamend NeuroN/AN/AN/AN/A$4.95 per shareN/ACTXRCitius PharmaceuticalsN/AN/AN/AN/A$2.52 per shareN/AGNTAGenenta ScienceN/AN/AN/AN/A$1.29 per shareN/AHOOKHOOKIPA Pharma$9.35M1.56N/AN/A$4.25 per share0.28Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALZNAlzamend Neuro-$4.51M-$2.16N/AN/AN/AN/A-177.52%-140.41%7/28/2026 (Estimated)CTXRCitius Pharmaceuticals-$37.43M-$2.13N/AN/AN/AN/A-61.09%-35.36%8/11/2026 (Estimated)GNTAGenenta Science-$7.39MN/AN/AN/AN/AN/AN/AN/AN/AHOOKHOOKIPA Pharma-$43.50M-$3.54N/AN/AN/A-785.66%-120.09%-77.14%5/26/2026 (Estimated)Latest ALZN, GNTA, HOOK, and CTXR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q2 2026CTXRCitius Pharmaceuticals-$0.2808-$0.95-$0.6693-$0.95$10.23 million$1.67 million3/31/2026Q4 2025GNTAGenenta Science-$0.3641-$0.0750+$0.2891-$0.0750N/AN/A3/11/2026Q3 2026ALZNAlzamend Neuro-$0.53-$0.5780-$0.0480-$0.58N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALZNAlzamend NeuroN/AN/AN/AN/AN/ACTXRCitius PharmaceuticalsN/AN/AN/AN/AN/AGNTAGenenta ScienceN/AN/AN/AN/AN/AHOOKHOOKIPA PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALZNAlzamend NeuroN/A1.991.99CTXRCitius PharmaceuticalsN/A0.580.16GNTAGenenta Science0.3514.1614.16HOOKHOOKIPA PharmaN/A3.613.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALZNAlzamend Neuro49.61%CTXRCitius Pharmaceuticals16.88%GNTAGenenta Science15.13%HOOKHOOKIPA Pharma63.88%Insider OwnershipCompanyInsider OwnershipALZNAlzamend Neuro1.39%CTXRCitius Pharmaceuticals4.99%GNTAGenenta Science28.99%HOOKHOOKIPA Pharma3.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALZNAlzamend Neuro43.80 million3.75 millionNo DataCTXRCitius Pharmaceuticals2027.45 million26.08 millionOptionableGNTAGenenta Science723.59 million16.75 millionNot OptionableHOOKHOOKIPA Pharma16012.33 million11.79 millionOptionableALZN, GNTA, HOOK, and CTXR HeadlinesRecent News About These CompaniesComparing ADC Therapeutics (NYSE:ADCT) & HOOKIPA Pharma (NASDAQ:HOOK)May 21, 2026 | americanbankingnews.comHOOKIPA PharmaApril 6, 2026 | fool.comHOOKIPA Pharma Announces Completion of Sale of Oncology Assets to NeoTrail TherapeuticsMarch 27, 2026 | markets.businessinsider.comGilead turns down chance to build on Assembly's phase 1-stage HBV antiviralMarch 21, 2026 | fiercebiotech.comFHOOKIPA Pharma Inc. Sells Immuno-Oncology Assets HB-200 and HB-700 to NeoTrail TherapeuticsFebruary 3, 2026 | quiverquant.comQHOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail TherapeuticsFebruary 3, 2026 | globenewswire.comHOOKIPA Pharma Inc. Completes Asset Sale of HB-400 and HB-500 Programs to Gilead SciencesOctober 31, 2025 | quiverquant.comQHOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to GileadOctober 31, 2025 | globenewswire.comVALANX Biotech appoints Klaus Orlinger, PhD. as Chief Scientific OfficerOctober 30, 2025 | cambridgenetwork.co.ukCVALANX Biotech names Klaus Orlinger as chief scientific officerOctober 30, 2025 | thepharmaletter.comTHOOKIPA Pharma Inc. (NASDAQ:HOOK) CFO Mary Theresa Coelho Sells 13,609 SharesJuly 24, 2025 | insidertrades.comHookipa, having sold off vaccines to Gilead, opts to wind downJuly 21, 2025 | fiercebiotech.comFSerial dealmaker Cathal Friel: ‘It’s important not to hand easy money to the next generation’July 18, 2025 | irishtimes.comHOOKIPA Pharma Inc. Announces Intent to Voluntarily Delist from Nasdaq and Pursue Asset Sale with Gilead SciencesJuly 18, 2025 | quiverquant.comQHOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common StockJuly 18, 2025 | globenewswire.comHookipa Pharma Inc News (HOOK) - Investing.comJune 24, 2025 | investing.comAdjuvant Nivolumab + CRT Improves Disease-Free Survival in Head and Neck CancerJune 2, 2025 | medscape.comMGilead (GILD) to Acquire HOOK for $10 millionMay 23, 2025 | msn.comGilead to buy certain Hookipa Pharma assets for up to $10MMay 22, 2025 | msn.comImmuneering appoints Igor Matushansky as CMOMarch 20, 2025 | thepharmaletter.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALZN, GNTA, HOOK, and CTXR Company DescriptionsAlzamend Neuro NASDAQ:ALZN$1.15 +0.02 (+1.77%) As of 04:00 PM EasternAlzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.Citius Pharmaceuticals NASDAQ:CTXR$0.70 0.00 (-0.58%) As of 04:00 PM EasternCitius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.Genenta Science NASDAQ:GNTA$0.60 +0.02 (+3.00%) As of 04:00 PM EasternGenenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.HOOKIPA Pharma NASDAQ:HOOK$1.18 +0.05 (+4.85%) As of 03:00 PM EasternHOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AutoZone's Pullback Sets Up a Long-Term Buying Opportunity AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus Powerhouse Williams-Sonoma Heading to Fresh Highs in 2026 Quantum Stocks Just Got a Lifeline—Who Benefits Most? Why BJ’s Wholesale Club Stock Could Be Ready for a Rebound 5 High-Yield Stocks and ETFs to Buy and Hold for the Next Decade Rocket Companies Turns Around, But Mortgage Risk Remains After NVIDIA, Broadcom's Earnings Are Next—Here's What to Watch Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
